Welcome to the Diabetes Trials Unit
The Diabetes Trials Unit (DTU) is a fully registered UKCRC Clinical Trials Unit (#14), specialising in performing national and multinational clinical trials related to diabetes, and a member of the Medical Sciences Division Clinical Trials Sub-Committee.[More about the DTU]
To hear more about what it is like to take part in a diabetes research study watch our video
If you would like to take part in one of our studies or find out more, please complete our enquiry form.
REF2014 Impact Case Studies
The REF is a system for assessing the quality of research in UK higher education institutions implemented for the first time in 2014.[Read more]
ADA 2018 Outstanding Achievement in Clinical Diabetes Research Award25-Jun-2018
Prof Rury Holman is the recipient of the 2018 Outstanding Achievement in Clinical Diabetes Research Award by the American Diabetes Association. This award recognizes exceptional contributions in patient-oriented or clinical outcomes research that have had a significant impact on diabetes prevention and treatment....
Exploring the impact of Diabetes UK research13-Apr-2018
Diabetes UK have released their first ever Research Impact Report which explores the impact of Diabetes UK research over the last 80 years. It was launched at a reception held on Thursday 15th March 2018 at the Diabetes UK Professional Conference....
Dr. M. Angelyn Bethel leaves the Diabetes Trials Unit06-Apr-2018
After 10 years at the Diabetes Trials Unit (DTU), Dr. Angelyn Bethel is leaving to pursue career opportunities in the pharmaceutical industry.
Dr. Bethel has the following message for her friends and co-workers: “My decision to leave the DTU was not taken lightly....
DTU Director discusses EXSCEL18-Jan-2018
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of once-weekly exenatide, administered in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, Professor Rury Holman shares his insights into the trial results.